Canada Jetlines and Boeing sign purchase agreement for purchase of up to twenty one (21) 737 MAX air

Inovent Capital Inc. (TSX Venture - IVQ.P, "Inovent") reports that Inovent is advised by its counterparty in a proposed amalgamation, Canada Jetlines Ltd. ("Jetlines"), that on December 11th, 2014, Jetlines signed a definitive purchase agreement with The Boeing Company ("Boeing") to acquire up to twenty-one (21) Boeing 737 MAX aircraft for delivery commencing in 2021 (the "Agreement"). The Agreement includes five (5) firm orders, purchase rights for an additional sixteen (16) 737 MAX and some conversion rights to the 737-8 MAX aircraft.

Inovent and Jetlines are working toward a previously disclosed amalgamation process, which, if completed, will constitute Inovent's Qualifying Transaction ("QT") pursuant to the policies of the TSX Venture Exchange ("TSXV"). In connection with QT, on November 26, 2014 Inovent filed a preliminary long form prospectus (the "Prospectus") in connection with a public offering of common shares of Inovent for aggregate gross proceeds of $50,000,000, subject to an over-allotment option, to establish operations in accordance with Jetlines' business plan and other costs (the "Financing").

"This Agreement with Boeing is a major milestone for Jetlines," said Jim Scott, CEO of Jetlines. "We are thrilled to be partnering with Boeing. The Agreement provides Jetlines access to leading edge aircraft technology in the future."

"Boeing is proud to partner with Jetlines as it begins a journey to offer low airfares to passengers across Canada," said Brad McMullen, vice president of North America Sales, Boeing Commercial Airplanes. "The 737 MAX 7 is perfectly suited to the airline's needs and we appreciate the confidence Jetlines has in the airplane."

The completion of the QT and the Financing is subject to a number of conditions, including but not limited to, TSXV acceptance and shareholder approval. The QT cannot close until the required shareholder approval is obtained. There can be no assurance that the QT will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the management information circular of Inovent dated November 24, 2014, (the "Circular") prepared in connection with the QT, including the Prospectus which is incorporated therein by reference, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

The TSXV has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

The Financing is being led by AltaCorp Capital Inc. and Euro Pacific Canada Inc as co-lead agents and joint bookrunners. Copies of the Circular, the Prospectus and related documents are available under the Inovent issuer profile at www.sedar.com